Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 10:40am ET with a live webcast at www.vcel.com/events.
- 29th Annual ROTH Conference in Dana Point, CA on Monday, March 13, 2017 at 8:00am PT with a live webcast at www.vcel.com/events.
- 2017 Canaccord Genuity Musculoskeletal Conference in San Diego, CA on Tuesday, March 14, 2017 at 11:00am PT with a live webcast at www.vcel.com/events.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults, which has recently been approved by the FDA. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
